Icosavax — Corporate Update (August 2023)
15 slides from Icosavax's corporate update, Aug 8, 2023
Slide 1: IVX-121 Phase 1b extension 12-month durability and revaccination update
The world needs better vaccines. We’re striving to create them. IVX-121 Phase 1b extension 12-month durability and revaccination update AUG 8, 2023 Exhibit 99.1
Slide 2: Forward looking statements
Forward looking statements Statements contained in this presentation regarding matters that are not historical facts are forward-looking statements. The forward-looking statements are based on the company’s current beliefs and expectations and include, but are not limited to: the company’s expectati
Slide 3: IVX-121 is the RSV VLP incorporated into IVX-A12 bivalent vaccine candidate
IVX-121 is the RSV VLP incorporated into our potential first-in-class IVX-A12 bivalent vaccine candidate targeting both RSV and hMPV OA: older adults; YA: younger adults MF59®: Seqirus Inc.’s proprietary adjuvant IVX-121 RSV Ph 1 / 1b completed (YA & OA) Ph 1b extension ongoing (OA) Icosavax clinica
Slide 4: Recap: IVX-A12 Phase 1 RSV immune response data
GMT (95% CI) No Adjuvant + MF59 75 µg IVX-121 150 µg 225 µg 300 µg 150 µg PBO 225 µg GMT (95% CI) No Adjuvant + MF59 75 µg IVX-121 150 µg 225 µg 300 µg 150 µg PBO 225 µg Day 0 and Day 28 Results Day 28 Day 0 RSV-B Recap: IVX-A12 Phase 1 topline interim data showed robust RSV immune response despite
Slide 5: Recap: IVX-A12 Phase 1 hMPV immunogenicity in older adults
GMT (95% CI) No Adjuvant + MF59 150 µg 225 µg 300 µg 150 µg PBO 225 µg GMT (95% CI) No Adjuvant + MF59 150 µg 225 µg 300 µg 150 µg PBO 225 µg Recap: IVX-A12 Phase 1 topline interim data provided first demonstration of hMPV vaccine immunogenicity in older adult population for the field Day 0 and Day
Slide 6: August 2023 data update: positive IVX-121 Ph 1b 12-month immunogenicity data
August 2023 data update: Positive IVX-121 Ph 1b 12-month immunogenicity data in older adults, and initial evidence for revaccination potential with VLP-based vaccine Substantial durability of RSV-A and RSV-B neutralizing antibody (NAb) titers up to 12 months (365 days) after initial vaccination with
Slide 7: IVX-121-01 Study Design: Phase 1b and extension
IVX-121-01 Study Design: Phase 1b, Phase 1b extension (D365 and Revaccination) alum: 500 µg/mL aluminum hydroxide. AE: adverse event; SAE: serious adverse event; AESI: adverse event of special interest; MAAE: medically-attended adverse event Full analysis set is shown for each stage above; immunogen
Slide 8: Topline immunogenicity data: RSV-A NAb through D365
Topline immunogenicity data: RSV-A NAb through D365 GMT expressed in IU/mL GMT: Geometric mean titer; LLoQ = 9.9; Assays conducted by Viroclinics. Data above reflect all subjects who met the per protocol criteria at the time of this 12-month analysis *Data shown represent unadjuvanted 75 µg and 250
Slide 9: Kinetics of RSV-A response over time through D393
Kinetics of RSV-A response over time through D393 (28 days after revaccination at D365) GMT expressed in IU/mL RSV-A LLoQ = 9.4 1All participants were dosed with unadjuvanted 75 µg IVX-121, regardless of previous formulation received GMT (IU/mL) Dose 2 (75 µg IVX-1211) Day 0 to Day 393 (28 days post
Slide 10: Conclusions and next steps
Conclusions and next steps NEXT STEPS: IVX-A12 Phase 2 topline interim data by end 2023; Phase 1 six-month immunogenicity update 1Q 2024 Positive 12-month data on IVX-121 provide additional support for differentiation potential of VLP technology on durability and revaccination data provides initial
Slide 11: Appendix
ats cS ep ICOSAVAX Appendix
Slide 12: Solicited adverse events within 7 days of revaccination
Dose 1 Dose 2 25 µg 75 µg 75 µg 75 µg 250 µg 75 µg PBO 75 µg Older Adult Revaccinated Subjects (ages 60-75) unadjuvanted IVX-121 groups, N=55 PH1b Ext. Solicited adverse events within 7 days of revaccination with unadjuvanted 75 µg IVX-121 Mild Moderate Severe Mild Moderate Severe Systemic Adverse E
Slide 13: IVX-121 GMT ranges for RSV-A and RSV-B in older adults
IVX-121 GMT ranges for RSV-A and RSV-B in older adults GMT expressed in IU/mL IVX-121 immunogenicity data above reflect all subjects who met the per protocol criteria for each stage at the time of this 12-month analysis. Number of participants per group across timepoints included in dataset: 25 µg:
Slide 14: Phase data for a recently-approved product shows diminished efficacy in second season
Phase 3 data for a recently-approved product shows diminished efficacy during a second season - trending similarly with lower NAb titers, and a reduced1 response to revaccination at 12 months 1Relative to initial response following a single dose; 2GSK June 2023 ACIP presentation, NCT04886596; 3GSK J
Slide 15: Nonclinical studies show IVX-A12 protection against both hMPV and RSV
Nonclinical studies demonstrate IVX-A12 achieved proof-of-concept protection against BOTH hMPV and RSV 1Two doses of IVX-121, IVX-241, or IVX-A12 (1 µg of each VLP) formulated with Addavax (oil-in-water adjuvant) were administered on day 0 and day 21, with RSV-A, RSV-B, or hMPV-A challenge two weeks